982 related articles for article (PubMed ID: 14723482)
1. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
Yadav S; Thukral R; Chakarvarti A
Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
[TBL] [Abstract][Full Text] [Related]
2. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
[TBL] [Abstract][Full Text] [Related]
3. Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 months of age.
Singh R; John TJ; Cherian T; Raghupathy P
Indian J Med Res; 1994 Oct; 100():155-9. PubMed ID: 7851964
[TBL] [Abstract][Full Text] [Related]
4. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
6. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
8. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
9. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
10. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
15. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
16. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
17. The two-dose measles, mumps, and rubella (MMR) immunisation schedule: factors affecting maternal intention to vaccinate.
Pareek M; Pattison HM
Br J Gen Pract; 2000 Dec; 50(461):969-71. PubMed ID: 11224968
[TBL] [Abstract][Full Text] [Related]
18. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
Jaber SM
Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
20. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]